US patent for Jordanian researcher in treatment of leukemia
Jordanian researcher Abdullah Khalaf Fariwan obtained a patent for a method of separating a specific type of immune cells called T cells and using them in immunotherapy for leukemia, or what is called acute lymphoblastic leukemia that affects the T-cell lymphocytes.
The researcher Feriwan, along with the St. Jude Hospital research team specializing in pediatric cancers, was able to prove the efficacy of using these cells to treat leukemia, and all the results were published in a peer-reviewed scientific journal (Blood Journal).
As a result of these results, the hospital administration decided to use this treatment method in clinical trials.
It is noteworthy that the researcher, Feriwan, is a graduate of the University of Science and Technology, majoring in medical laboratories, and completed his studies in the United States, and joined the field of laboratory research at St. Jude Hospital in Tennessee.
Jordanian researcher Abdullah Khalaf Fariwan obtained a patent for a method of separating a specific type of immune cells called T cells and using them in immunotherapy for leukemia, or what is called acute lymphoblastic leukemia that affects the T-cell lymphocytes.
The researcher Feriwan, along with the St. Jude Hospital research team specializing in pediatric cancers, was able to prove the efficacy of using these cells to treat leukemia, and all the results were published in a peer-reviewed scientific journal (Blood Journal).
As a result of these results, the hospital administration decided to use this treatment method in clinical trials.
It is noteworthy that the researcher, Feriwan, is a graduate of the University of Science and Technology, majoring in medical laboratories, and completed his studies in the United States, and joined the field of laboratory research at St. Jude Hospital in Tennessee.
Jordanian researcher Abdullah Khalaf Fariwan obtained a patent for a method of separating a specific type of immune cells called T cells and using them in immunotherapy for leukemia, or what is called acute lymphoblastic leukemia that affects the T-cell lymphocytes.
The researcher Feriwan, along with the St. Jude Hospital research team specializing in pediatric cancers, was able to prove the efficacy of using these cells to treat leukemia, and all the results were published in a peer-reviewed scientific journal (Blood Journal).
As a result of these results, the hospital administration decided to use this treatment method in clinical trials.
It is noteworthy that the researcher, Feriwan, is a graduate of the University of Science and Technology, majoring in medical laboratories, and completed his studies in the United States, and joined the field of laboratory research at St. Jude Hospital in Tennessee.
comments
US patent for Jordanian researcher in treatment of leukemia
comments